SECOND AMENDMENT TO THE LICENSE, MARKETING AND DEVELOPMENT AGREEMENTLicense, Marketing and Development Agreement • August 6th, 2015 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus
This Second Amendment (“Second Amendment”) to the License, Marketing and Development Agreement dated November 14, 2013 (the “Original Agreement”) is effective as of April 30, 2015 (the “Second Amendment Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
